<p>根據其最近向證券交易委員會提交的 13F 文件，MPM Bioimpact LLC 在第四季度購買了 Veru Inc.（NASDAQ:VERU - 免費報告）的新股份。該公司購買了 4,285,365 股，價值約為 2,788,000 美元。到最近一個季度末，MPM Bioimpact LLC 持有 Veru 約 2.93% 的股份。</p>
<p>其他一些對沖基金和機構投資者最近也調整了他們對 VERU 的持股。Cetera Investment Advisers 在第四季度將其在 Veru 的持股增加了 26.1%。Cetera Investment Advisers 現在擁有 95,210 股該公司的股票，價值 62,000 美元，此前在上個季度購買了額外的 19,724 股。美國銀行（Bank of America Corp DE）在第四季度將其在 Veru 的持股增加了 17.5%。美國銀行現在擁有 217,792 股該公司的股票，價值 142,000 美元，此前在此期間購買了額外的 32,447 股。Jane Street Group LLC 在第四季度將其在 Veru 的持股增加了 35.2%。Jane Street Group LLC 現在擁有 130,406 股該公司的股票，價值 85,000 美元，此前在此期間獲得了額外的 33,952 股。Integrated Wealth Concepts LLC 在第四季度將其在 Veru 的持股增加了 31.3%。Integrated Wealth Concepts LLC 現在擁有 85,900 股該公司的股票，價值 56,000 美元，此前在上個季度購買了額外的 20,500 股。最後，NewEdge Advisors LLC 在第四季度將其在 Veru 的持股增加了 2,500.0%。NewEdge Advisors LLC 現在擁有 130,000 股該公司的股票，價值 85,000 美元，此前在此期間購買了額外的 125,000 股。機構投資者持有該公司 47.16% 的股份。</p>
<h2>Veru 股票表現</h2>
<p>NASDAQ:VERU 週三開盤價為 0.52 美元。Veru Inc.的 52 周低點為 0.45 美元，52 周高點為 1.57 美元。該公司的市值為 7548 萬美元，市盈率為-1.98，貝塔值為-0.74。該股票的 50 日移動平均線為 0.53 美元，200 日移動平均線為 0.63 美元。</p>
<p>Veru（NASDAQ:VERU - 獲取免費報告）最近於 5 月 8 日（星期四）發佈了其財報。該公司報告本季度每股收益為（0.05）美元，超出分析師一致預期的（0.06）美元，超出幅度為 0.01 美元。Veru 的股本回報率為-112.75%，淨利潤率為-223.85%。股票分析師預測 Veru Inc.在當前財政年度的每股收益將為-0.22 美元。</p>
<h2>Veru 內部交易</h2>
<p>在其他 Veru 新聞中，董事 Michael L. Rankowitz 於 2 月 18 日（星期二）購買了 95,279 股該股票。該股票的平均購買成本為每股 0.55 美元，總價值為 52,403.45 美元。收購後，該董事現在持有 195,279 股該公司的股票，價值約為 107,403.45 美元。這筆交易代表了他們持股的 95.28% 的增長。該購買在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。公司內部人士持有該公司 14.90% 的股份。</p>
<h2>Veru 簡介</h2>
<p>（免費報告）</p>
<p>Veru Inc.是一家處於臨牀後期的生物製藥公司，專注於開發治療代謝疾病、腫瘤學和急性呼吸窘迫綜合症（ARDS）的藥物。其市場產品包括 FC2 女性避孕套，用於防止意外懷孕和傳播性傳播感染的雙重保護。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Veru</li>
<li>高股息 REIT：它們是理想的多元化方式嗎？</li>
<li>製藥火售：3 只 RSI 認為你不應忽視的股票</li>
<li>什麼是財報？</li>
<li>AppLovin 因財報激增：這家科技公司接下來會怎樣？</li>
<li>寶潔公司（Procter &amp; Gamble NYSE: PG）在不穩定的指引後回落</li>
<li>美國監管機構針對 CrowdStrike：這是信號還是噪音？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSVQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSVQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Veru 嗎？</h2>
<p>在你考慮 Veru 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Veru 並不在名單上。</p>
<p>雖然 Veru 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

VERU

<p>MPM Bioimpact LLC 在第四季度收購了 4,285,365 股 Veru Inc.（納斯達克代碼：VERU），價值約 279 萬美元，佔公司約 2.93% 的股份。其他機構投資者也增加了對 Veru 的持股。該股票開盤價為 0.52 美元，52 周價格區間為 0.45 至 1.57 美元。Veru 報告的季度每股虧損為 0.05 美元，超出預期，分析師預測本財年將虧損 0.22 美元。內部人士持有 14.90% 的股份，公司專注於開發代謝疾病和腫瘤學的治療方案</p>

<p>MPM Bioimpact LLC purchased a new stake in Veru Inc. (NASDAQ:VERU - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,285,365 shares of the company's stock, valued at approximately $2,788,000. MPM Bioimpact LLC owned approximately 2.93% of Veru at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據其最近向證券交易委員會提交的 13F 文件，MPM Bioimpact LLC 在第四季度購買了 Veru Inc.（NASDAQ:VERU - 免費報告）的新股份。該公司購買了 4,285,365 股，價值約為 2,788,000 美元。到最近一個季度末，MPM Bioimpact LLC 持有 Veru 約 2.93% 的股份。</p>
</div><p>A number of other hedge funds and other institutional investors have also recently modified their holdings of VERU. Cetera Investment Advisers raised its holdings in Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after purchasing an additional 19,724 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Veru by 17.5% in the 4th quarter. Bank of America Corp DE now owns 217,792 shares of the company's stock worth $142,000 after purchasing an additional 32,447 shares during the period. Jane Street Group LLC grew its stake in shares of Veru by 35.2% during the 4th quarter. Jane Street Group LLC now owns 130,406 shares of the company's stock worth $85,000 after acquiring an additional 33,952 shares during the period. Integrated Wealth Concepts LLC grew its stake in Veru by 31.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock valued at $56,000 after buying an additional 20,500 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Veru by 2,500.0% during the 4th quarter. NewEdge Advisors LLC now owns 130,000 shares of the company's stock valued at $85,000 after purchasing an additional 125,000 shares during the period. Institutional investors own 47.16% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也調整了他們對 VERU 的持股。Cetera Investment Advisers 在第四季度將其在 Veru 的持股增加了 26.1%。Cetera Investment Advisers 現在擁有 95,210 股該公司的股票，價值 62,000 美元，此前在上個季度購買了額外的 19,724 股。美國銀行（Bank of America Corp DE）在第四季度將其在 Veru 的持股增加了 17.5%。美國銀行現在擁有 217,792 股該公司的股票，價值 142,000 美元，此前在此期間購買了額外的 32,447 股。Jane Street Group LLC 在第四季度將其在 Veru 的持股增加了 35.2%。Jane Street Group LLC 現在擁有 130,406 股該公司的股票，價值 85,000 美元，此前在此期間獲得了額外的 33,952 股。Integrated Wealth Concepts LLC 在第四季度將其在 Veru 的持股增加了 31.3%。Integrated Wealth Concepts LLC 現在擁有 85,900 股該公司的股票，價值 56,000 美元，此前在上個季度購買了額外的 20,500 股。最後，NewEdge Advisors LLC 在第四季度將其在 Veru 的持股增加了 2,500.0%。NewEdge Advisors LLC 現在擁有 130,000 股該公司的股票，價值 85,000 美元，此前在此期間購買了額外的 125,000 股。機構投資者持有該公司 47.16% 的股份。</p>
</div><h2>Veru Stock Performance</h2>
<div class="lb-trans"><h2>Veru 股票表現</h2>
</div><p>NASDAQ:VERU opened at $0.52 on Wednesday. Veru Inc. has a 52-week low of $0.45 and a 52-week high of $1.57. The firm has a market capitalization of $75.48 million, a price-to-earnings ratio of -1.98 and a beta of -0.74. The stock has a fifty day moving average of $0.53 and a 200 day moving average of $0.63.</p>
<div class="lb-trans"><p>NASDAQ:VERU 週三開盤價為 0.52 美元。Veru Inc.的 52 周低點為 0.45 美元，52 周高點為 1.57 美元。該公司的市值為 7548 萬美元，市盈率為-1.98，貝塔值為-0.74。該股票的 50 日移動平均線為 0.53 美元，200 日移動平均線為 0.63 美元。</p>
</div><p>Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. Equities analysts forecast that Veru Inc. will post -0.22 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Veru（NASDAQ:VERU - 獲取免費報告）最近於 5 月 8 日（星期四）發佈了其財報。該公司報告本季度每股收益為（0.05）美元，超出分析師一致預期的（0.06）美元，超出幅度為 0.01 美元。Veru 的股本回報率為-112.75%，淨利潤率為-223.85%。股票分析師預測 Veru Inc.在當前財政年度的每股收益將為-0.22 美元。</p>
</div><h2>Insider Transactions at Veru</h2>
<div class="lb-trans"><h2>Veru 內部交易</h2>
</div><p>In other Veru news, Director Michael L. Rankowitz purchased 95,279 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $0.55 per share, with a total value of $52,403.45. Following the acquisition, the director now owns 195,279 shares in the company, valued at approximately $107,403.45. This trade represents a 95.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Company insiders own 14.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Veru 新聞中，董事 Michael L. Rankowitz 於 2 月 18 日（星期二）購買了 95,279 股該股票。該股票的平均購買成本為每股 0.55 美元，總價值為 52,403.45 美元。收購後，該董事現在持有 195,279 股該公司的股票，價值約為 107,403.45 美元。這筆交易代表了他們持股的 95.28% 的增長。該購買在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。公司內部人士持有該公司 14.90% 的股份。</p>
</div><h2>Veru Profile</h2>
<div class="lb-trans"><h2>Veru 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.</p>
<div class="lb-trans"><p>Veru Inc.是一家處於臨牀後期的生物製藥公司，專注於開發治療代謝疾病、腫瘤學和急性呼吸窘迫綜合症（ARDS）的藥物。其市場產品包括 FC2 女性避孕套，用於防止意外懷孕和傳播性傳播感染的雙重保護。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Veru</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
<li>What Are Earnings Reports?</li>
<li>AppLovin Surges on Earnings: What's Next for This Tech Standout?</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Veru</li>
<li>高股息 REIT：它們是理想的多元化方式嗎？</li>
<li>製藥火售：3 只 RSI 認為你不應忽視的股票</li>
<li>什麼是財報？</li>
<li>AppLovin 因財報激增：這家科技公司接下來會怎樣？</li>
<li>寶潔公司（Procter &amp; Gamble NYSE: PG）在不穩定的指引後回落</li>
<li>美國監管機構針對 CrowdStrike：這是信號還是噪音？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSVQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VERU"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Veru Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Veru 嗎？</h2>
</div><p>Before you consider Veru, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Veru 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Veru 並不在名單上。</p>
</div><p>While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Veru 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MPM Bioimpact LLC 收購了 Veru Inc.（NASDAQ:VERU）的 4,285,365 股股票